文献速递免疫规划卫生政策与健康促进

20个中低收入国家和20个高收入国家针对难民的常规免疫政策分析

Country immunization policies for refugees across 20 low-middle income and 20 high-income countries.
PubMed 文献 · Vaccine · 2022-09-16

研究收集并分析了难民人数最多的20个中低收入国家和20个高收入国家针对难民的常规免疫政策。20个中低收入国家中有13个制定了全国性难民常规免疫政策,20个高收入国家中有14个将难民纳入国家常规免疫规划。作者认为两类国家均应把难民纳入国家常规免疫政策并提供可及、可负担的免疫接种。

要点

  • 20个中低收入国家中13个制定了全国性难民常规免疫政策。
  • 20个高收入国家中14个将难民纳入国家常规免疫规划。
  • 作者认为中低收入国家和高收入国家均应把难民纳入国家常规免疫政策。

核心结论

  • 中低收入国家和高收入国家均应把难民纳入国家常规免疫政策,并提供可及、可负担的免疫接种,以减少疫苗可预防疾病并保护难民健康,尤其在COVID-19大流行期间。

研究设计与样本

  • 收集并分析难民人数最多(每1000名居民中难民数最高)的20个中低收入国家和20个高收入国家针对难民的现有常规免疫政策,采用一手和二手数据来源收集政策证据。

主要发现

  • 20个中低收入国家中有13个明确制定了全国性难民常规免疫政策。
  • 20个高收入国家中有14个将难民纳入国家常规免疫规划。

临床怎么用

  • 作者认为中低收入国家和高收入国家均应把难民纳入国家常规免疫政策,并提供可及、可负担的免疫接种。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2020, 26 million refugees resettled in a new country-fleeing their homes due to conflict and persecution. Due to low immunization coverage and underlying health conditions, refugees commonly face an increased risk of contracting vaccine-preventable diseases. We collected and analyzed existing routine immunization policies for refugees across 20 low- and middle-income countries (LMICs) and 20 high-income countries (HICs), each with the highest number of refugees per 1000 residents. Primary and secondary data sources were used to collect policy evidence. Across 20 LMICs, 13 countries specified standing nationwide routine immunization policies for refugees, while 14 out of the 20 HICs included refugees in their national routine immunization programs. LMICs and HICs should include refugees in their national routine immunization policies and provide accessible and affordable immunizations. Such efforts would reduce vaccine-preventable diseases and protect the health of refugee populations-especially during the COVID-19 pandemic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Elharake JA, Omer SB, Schwartz JL, et al. Country immunization policies for refugees across 20 low-middle income and 20 high-income countries. Vaccine. 2022. PMID: 36123257. doi:10.1016/j.vaccine.2022.09.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。